| Name | Title | Contact Details |
|---|---|---|
Zohar Krivorot |
President and Chief Executive Officer | Profile |
Fluidx Medical Technologys novel GPX Embolic Device is a durable embolic that is easy to use, controllable, and effective for vessel occlusion.
Windgap Medical is developing health care products that meet the demands of your lifestyle. Our first product will improve the quality of life for patients living with severe allergies.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Mylan Specialty is a Basking Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Applied Medical - Corporate Site